Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of NASH, and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases
Candidates often include individuals with a body mass index (BMI) of 30 or higher, or 27 or higher with weight-related health concerns
This makes the strength of the small molecule patent estates even more critical to retain hard-won market share after loss of the COM patent
Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation, vol
10.1177/030006058401200312 J Int Med Res
US$ 24.78
US$ 20.53
US$ 22.43
US$ 23.66
US$ 26.14
US$ 25.14
US$ 25.46
US$ 1149.99
Sold : Login>>
